Browse All
Displaying 1 - 1 of 1
Author:Pardo, Gabriel Montalban, Xavier Cohen, Jeffrey Morrow, Sarah Li, Jun Carr, David Pearce, Gregory Solonets, Maria Abeyewickreme, Anil de Seze, Jérôme Nakahara, Jin Wiendl, Heinz Hauser, Stephen
Session Name:P9: Multiple Sclerosis: Clinical Trials 2
Topic:Multiple Sclerosis
Program Number:P9.006
Author Institution:Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK Department of Neurology/Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, calgary, AB, Canada Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland IQVIA RDS GmbH, Frankfurt, Germany, Germany Novartis Pharmaceuticals UK Ltd, London, United Kingdom, London, United Kingdom University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Shinjuku-ku, Japan Klinik für Neurologie und Neurophysiologie, Universitätsklinikum Freiburg, Freiburg, Germany, Freiburg im Breisgau, Germany UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA
